NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
FDA approved the Company’s first drug, preservative-free ketamine, ahead of its GDUFA goal date; commercial launch underway with a 17-person sales forceNew Yale University collaboration supports the Accelerated Approval pathway for NRX-100; new pipeline product NRX-200 announced for subcutaneous ke…